On November 29, 2025, the international seminar "Tumor Intelligence: Empowering Precision Medicine Transformation with Artificial Intelligence and Innovative Technologies," hosted by Suzhou Labyrinth Biotech Co., Ltd., was successfully held in Suzhou and concluded successfully.

This conference focuses on the clinical applications of tumor biology, artificial intelligence, ADC drugs, liquid biopsy, and innovative engineering technologies, attracting many authoritative experts from both domestic and international fields to discuss the development direction of next-generation precision medicine together.

At the beginning of the meeting, several guests from the medical, public welfare, and industry sectors delivered speeches at the conference.

1. Mr. Guan Changping, Director of the Wu Jieping Medical Foundation, congratulated the successful convening of the conference in his speech, highly praised Labyrinth's continuous investment in rare cell liquid biopsy and precision medicine, and expressed his hope that the company would continue to reach new heights in international cooperation and technology translation.

2. Professor Song Ming, Director of the Department of Head and Neck at Sun Yat-sen University Cancer Prevention and Treatment Center, also attended with his team, and reported on the breakthrough progress of two projects in collaboration with the Labyrinth team. He highly praised the company's technological performance and expressed hope to continue working together to advance more innovative results into clinical practice in the future.

3. Mr. Yang Hongkun, Chairman of Qiyuan Health Management Company, shared real cases of his organization applying Labyrinth technology in health management and cancer risk screening scenarios, demonstrating the practical value of the rare cell platform in population screening and individualized management, and also providing a new model for deep cooperation between the industry side and technology providers.

4. A representative of the conference organizers, Labyrinth CTO Dr. Majid E. Warkiani, also delivered a speech. He expressed his sincere thanks to the domestic and international guests who came from afar. Dr. Warkiani pointed out that Labyrinth's microfluidic platform is continuously achieving new results in multiple cancer detection, CTC capture, in vitro culture, and drug sensitivity testing. The company will continue to promote the technology from the laboratory to clinical application, serving patients in China and around the world with greater speed and higher quality.

During the academic exchange session, several domestic and international experts from the fields of tumor biology, ADC drugs, artificial intelligence, and other areas each shared the latest research progress of their respective teams, bringing a highly in-depth interdisciplinary perspective to this conference.

In the field of basic tumor research, Professor Jean-Paul Thiery, an honorary scientist of the French National Academy of Sciences, has laid a strong scientific foundation for the seminar with his long-term contributions in the areas of metastasis mechanisms and tumor plasticity. In the ADC clinical and drug development section, Dr. Li Jiajia from Fudan University Cancer Hospital approached from the forefront of gynecological tumor treatment, sharing China's key explorations in the clinical application of ADCs and expressing hope that Labyrinth's CTC platform can provide more experimental support in the study of ADC targeting mechanisms and early exploratory evaluation. The artificial intelligence session is presented by Dr. He Zhaoren from Baitu Shengke, introducing the latest advances in large-scale life science models and demonstrating the potential of AI to reshape future tumor diagnosis and treatment patterns.

During the discussions and exchanges with the guests, several scholars actively mentioned the importance of liquid biopsy technology in tumor monitoring, drug resistance tracking, and drug evaluation, and expressed attention to and recognition of Labyrinth’s technological layout and practical achievements in CTC analysis and capture, in vitro cultivation, and clinical application exploration. Moreover, in the subsequent Q&A session, many guests asked questions and shared their thoughts based on their respective research directions, creating a lively discussion atmosphere. The convergence of different backgrounds and perspectives has brought about intense clashes of opinions, and has also given rise to many new ideas and potential directions for collaboration.

The successful holding of this seminar not only provided a cutting-edge platform for in-depth communication among global experts and scholars, but also witnessed the direction of industrial application of label-free microfluidic technology in the field of precision tumor medicine.

Through the collision of interdisciplinary ideas and the deep integration of industry, academia, and research, this technology is opening a new chapter in precision medicine. As an important breakthrough in the field of precision medicine, this technology is redefining the boundaries of disease diagnosis and treatment. Suzhou Labyrinth will continue to deepen technological innovation and international collaboration, promoting the accessibility and inclusive development of global precision medicine with "Made in China" intelligence.